Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
18 hedge funds and large institutions have $1.54M invested in Interpace Biosciences, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.
5% less funds holding
Funds holding: 19 → 18 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
48% less capital invested
Capital invested by funds: $2.98M → $1.54M (-$1.43M)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.79K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$2.78K |
| 3 |
Renaissance Technologies
New York
|
+$1.36K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$803 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$77K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$42.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.9K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$8.75K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$6K |
IDXG Hedge Fund Activity: Q1 2016 in Review
18 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2016, worth a combined $1.54M — down 48% from $2.98M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IDXG and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $4.79K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $77K sold.
- 18 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2016, down from 19 in Q4 2015.
- Funds reported $1.54M of Interpace Biosciences, Inc. Common Stock stock for Q1 2016, down 48% quarter-over-quarter.
- 3 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2016 and 4 closed out, a net change of -1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2016 was Goldman Sachs, an estimated $4.79K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2016 was Bridgeway Capital Management, an estimated $77K sold.
Based on aggregated 13F filings for Q1 2016.